Hot spot-driven discovery of β-catenin/Tcf4 interaction inhibitors via virtual drug repurposing study and experimental validation in colorectal cancer cells.

K. Şahin A. Coker S. Durdağı

Sep 2026 · Molecular diversity · 0 citations · 32 references

Medicine

TL;DR

Findings provide compelling evidence for the feasibility of targeting β-catenin/Tcf4 interactions using small molecules and suggest that Carbenicillin and Ceforanide may serve as promising repurposed candidates for therapeutic intervention in Wnt-driven malignancies.

DOI PubMed Semantic Scholar

View source

Similar papers

Sep 2026

Structure-based discovery of potent SMO inhibitors guided by MM/GBSA binding free energies in hedgehog-driven cancers.

These findings position ZINC7263 as a novel, potent SMO inhibitor with a stable binding affinity, dynamic interaction stability, and promising preclinical potential for targeting Hh-driven cancers.

Arpit Sharma, Alok Shukla, S. Raut et al. · Computational biology and ch... · 0 citations

Open access Sep 2026

Experimental assessment of computationally nominated small molecules targeting the YAP–TEAD interface in Hippo pathway-altered mesothelioma cell models

Aberrant activation of the Hippo–YAP/TAZ–TEAD transcriptional axis is a recurrent feature of multiple solid tumors and contributes to tumor maintenance, lineage plasticity, and therapeutic resistance. Recent medicinal chemistry has shown that TEAD proteins are druggable, but the rate at which in silico screening nomina...

Glen J. Weiss, Joseph C. Loftus, D. Mallery et al. · Frontiers in Oncology · 0 citations

Aug 2026

In Silico Exploration of Novel EGFR T790M and C797S Resistance with Mutant-Selective Allosteric Inhibitors Using a Hybrid Computational Approach

A number of lead candidates with strong EGFR inhibitory potential, promising pharmacokinetic profiles, and mutant selectivity were successfully identified by the integrated computational approach.

M. Kendre, S. S. Bhusari, Pravin S. Wakte · Journal of Pharmaceutical In... · 0 citations

Aug 2026

Targeting the c-Myb-CBP/p300 KIX protein-protein interaction with quinone-methide triterpenes: In silico mechanistic insights and MST biochemical validation.

Tingenone is identified as a promising scaffold for the development of new c-Myb-CBP/p300 KIX PPI inhibitors, having produced the clearest signatures of interfacial weakening and the most favorable disruption metrics.

Emadeldin M. Kamel, H. Rudayni, A. A. Allam et al. · Journal of Molecular Graphic... · 0 citations

Open access Sep 2026

Structure-guided identification and experimental validation of NAT10-targeting small molecules in colorectal cancer cells

G856-6814 is supported as a NAT10-targeting inhibitory scaffold that requires broader selectivity and in vivo evaluation and attenuation of cellular effects after NAT10 knockdown.

Chao Xu, Shi-Lei Zhao, Bing Xu et al. · Journal of Computer-Aided Mo... · 0 citations

Open access Aug 2026

Network pharmacology and experimental evidence of the anti-colorectal cancer potential of Xian Lian Jie Du formula: quercetin, kaempferol and luteolin jointly inhibit the HIF1A/IL6/TNF oncogenic pathway

A large amount of XLJD and every three flavonoids significantly reduced the mRNA expression of the five hub genes in HT-29 cells; however, the low-concentration group had little to no effect.

Ning Du, L. Ji, Li-Xing Liu et al. · Frontiers in Oncology · 0 citations